Clinical Applications of Natriuretic Peptides in Heart Failure and Atrial Fibrillation.
Masako BabaKentaro YoshidaMasaki IedaPublished in: International journal of molecular sciences (2019)
Natriuretic peptides (NPs) have become important diagnostic and prognostic biomarkers in cardiovascular diseases, particularly in heart failure (HF). Diagnosis and management of coronary artery disease and atrial fibrillation (AF) can also be guided by NP levels. When interpreting NP levels, however, the caveat is that age, sex, body mass index, renal dysfunction, and race affect the clearance of NPs, resulting in different cut-off values in clinical practice. In AF, NP levels have been associated with incident AF in the general population, recurrences after catheter ablation, prediction of clinical prognosis, and the risk of stroke. In this article, we first review and summarize the current evidence and the roles of B-type NP and atrial NP in HF and coronary artery disease and then focus on the increasing utility of NPs in the diagnosis and management of and the research into AF.
Keyphrases
- atrial fibrillation
- catheter ablation
- heart failure
- coronary artery disease
- left atrial
- oral anticoagulants
- left atrial appendage
- percutaneous coronary intervention
- body mass index
- cardiovascular disease
- direct oral anticoagulants
- clinical practice
- acute heart failure
- left ventricular
- amino acid
- ejection fraction
- acute coronary syndrome
- metabolic syndrome
- weight loss
- aortic valve
- blood brain barrier